Boston Scientific Corp (BSX) recently reported a surpassing of revenue estimates for the fourth quarter and the full year of 2024, showcasing a record revenue growth. Several investment management firms have been steadily increasing their shares in Boston Scientific, reflecting a robust expression of confidence in the company's future prospects. Forecasts from TD Cowen, UBS Group, Morgan Stanley, Wells Fargo & Company, Citigroup, Royal Bank of Canada, and Raymond James have raised BSX's price target, signaling bullish expectations. However, despite these projections, certain firms report cutting stock holdings, and some insider selling was reported. The company has been engaged in major acquisitions, including those of Intera Oncology® Inc. and Cortex, Inc., seeking growth through access to innovative solutions. However, despite topping Q4 earnings and revenues, the BSX stock fell due to weak gross margin
Boston Scientific Corp BSX News Analytics from Wed, 23 Oct 2024 07:00:00 GMT to Sat, 08 Feb 2025 20:56:57 GMT - Rating 7 - Innovation 6 - Information 8 - Rumor -2
